Original paper

IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report

Volume: 20, Issue: 1
Published: Apr 25, 2020
Abstract
Background Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small cell lung cancer. The unique adverse events that can arise after treatment with ICIs are known as immune-related adverse events (irAE). As the number of cases under treatment with ICIs increases, new types of characteristics of irAE have emerged. This case report suggests that IgG4-related pleural disease could occur as an irAE. Case presentation A...
Paper Details
Title
IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report
Published Date
Apr 25, 2020
Volume
20
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.